Data for iTRAQ-based quantification of the effect of HuganQingzhi on non-alcoholic fatty liver disease in rats
Xiaorui Yao,
Fan Xia,
Waijiao Tang,
Chunxin Xiao,
Miaoting Yang,
Benjie Zhou
Affiliations
Xiaorui Yao
Department of Pharmacy, Shantou Central Hospital, Affiliated Shantou Hospital of Sun Yat-Sen University, Shantou 515041, Guangdong, PR China
Fan Xia
Department of Pharmacy, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, Guangdong, PR China
Waijiao Tang
Center for Drug Research and Development, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, Guangdong, PR China
Chunxin Xiao
Center for Drug Research and Development, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, Guangdong, PR China
Miaoting Yang
Center for Drug Research and Development, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, Guangdong, PR China
Benjie Zhou
Center for Drug Research and Development, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, Guangdong, PR China; Corresponding author. Tel.: +86 02061634549; fax: +86 02084300639.
The data presented in this article are related to the research article entitled âIsobarictags for relative and absolute quantitation (iTRAQ) -based proteomics for the investigation of the effect of HuganQingzhi on non-alcoholic fatty liver disease in ratsâ (Yao et al., 2017) [1]. This article describes the effect of HuganQingzhi on non-alcoholic fatty liver disease in rats at the level of the proteome (HFD: control, HH: control, HH: HFD, respectively). The field dataset is available to criticize or extended analyzes in public.
